Repligen Corporation (RGEN) - 10-K Summary
Business Context and Reporting Period
Period: Fiscal year ended March 31, 1995.
Business: Biopharmaceutical company focused on research, development, and manufacture of therapeutic products for cancer, cardiovascular conditions, and immunology.
Key Programs:
- rPF4: Recombinant Platelet Factor-4 for heparin neutralization and cancer therapy (angiogenesis inhibition). Funded primarily by Repligen Clinical Partners, L.P. (the "Partnership").
- Inflammation Inhibition (m60.1/h60.1): Monoclonal antibodies targeting CD11b for conditions like chronic lung inflammation and aortic aneurysms. Collaborated with Eli Lilly.
- Commercial Products: Recombinant Protein A and diagnostic reagents.
Key Financial Metrics
| Metric (in thousands) | Fiscal 1995 | Fiscal 1994 |
|---|---|---|
| Total Revenues | $16,942 | $26,833 |
| Net Loss | $(31,950) | $(19,537) |
| Net Loss Per Share | $(2.08) | $(1.53) |
| Cash and Investments | $15,302 | $29,215 |
| Working Capital | $9,070 | $32,517 |
| Long-Term Debt | $0 | $0 |
| Accumulated Deficit | $(111,520) | $(79,570) |
Note: Long-term debt of $4.62 million was paid in full in May 1995. A $4 million line of credit was unused at period end.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 37% to $16.9 million. R&D revenue dropped 43% due to reduced funding from Eli Lilly (as product entered Phase I/II) and the Partnership (management chose to self-fund portions to preserve Partnership capital).
- Restructuring Charge: A significant non-recurring charge of $11.3 million was recorded. This included $6.5 million in cash expenditures (severance for ~140 employees, lease losses, contract termination fees) and $4.8 million in non-cash write-offs of assets.
- Liquidity Deterioration: Cash and investments fell 48% to $15.3 million. Working capital decreased from $32.5 million to $9.1 million.
- Program Termination: The Small Molecule (AM285) and HIV Vaccine programs were discontinued in 1994 to focus resources on lead candidates.
Outlook, Risks, and Management Commentary
Liquidity Risk: Management explicitly states that without additional financing in calendar 1995 or early 1996 (via equity offering, third-party funding, or merger), the Company will be forced to curtail or cease operations. Current funds are estimated to last only until March 31, 1996.
Partnership Funding: The Company requires approximately $60 million to complete the rPF4 program. Discussions for a joint venture with a pharmaceutical company are in preliminary stages. The Partnership's ability to fund the program is contingent on limited partners making final installment payments; as of June 9, 1995, $10.8 million of the final $13.4 million due had been received.
Lease Covenants: The Company was not in compliance with certain financial covenants on equipment leases as of March 31, 1995, and anticipates default in 1996, which would make future lease payments immediately due ($5.7 million total obligation).
Intellectual Property: The Company holds ~75 patents but faces standard biotech risks regarding patent validity, infringement claims, and the uncertainty of FDA approval for clinical candidates.
Investor Verification Checklist
- Cash Runway: Verify the status of the $2.6 million in unpaid Partnership installments and the timeline for securing the estimated $60 million needed for rPF4 completion.
- Lease Default: Confirm the outcome of negotiations with lessors regarding the $5.7 million in accelerated lease payments triggered by covenant non-compliance.
- Restructuring Execution: Monitor the actual cash outflow for the $6.5 million restructuring charge and the impact on remaining liquidity.
- Joint Venture Progress: Assess the status of preliminary discussions with pharmaceutical partners for funding the rPF4 program.
- Warrant Modifications: Review the acceptance rate of the 1995 warrant modification offer (601 of 811 units accepted as of June 9, 1995) and its impact on future dilution and royalty obligations.